Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO AND ACTIVE-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN

Next Previous
Trial Profile

A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO AND ACTIVE-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tanezumab (Primary) ; Tanezumab (Primary) ; Tramadol
  • Indications Back pain
  • Focus Registrational; Therapeutic Use
  • Acronyms TANGO
  • Sponsors Pfizer

    • Most Recent Events

    • 22 Dec 2022 Results of meta analysis (n=3414 from 3 studies NCT00584870,NCT00876187 and NCT02528253) assessing Different Dosage Regimens of Tanezumab for the Treatment of Chronic Low Back Pain published in the Clinical Neuropharmacology
    • 13 Aug 2022 Results evaluating the clinical meaningfulness of treatment response , focused on secondary measures of pain, interference with daily functions, overall disease status, and satisfaction with treatment, published in the Pain and Therapy
    • 06 Jun 2020 Results of an analysis of Brief Pain Inventory-Short Form Scores from this study, were presented at the 21st Annual Congress of the European League Against Rheumatism.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top